<SEC-DOCUMENT>0001193125-24-129361.txt : 20240502
<SEC-HEADER>0001193125-24-129361.hdr.sgml : 20240502
<ACCEPTANCE-DATETIME>20240502160856
ACCESSION NUMBER:		0001193125-24-129361
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240502
DATE AS OF CHANGE:		20240502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39979
		FILM NUMBER:		24908259

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d819945ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.___) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a party other than the Registrant&#8194;&#9744; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>VOR BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Rules&nbsp;14a-6(i)(1)&nbsp;and&nbsp;0-11.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g819945g0430225727078.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOR BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 Cambridgepark Drive, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cambridge, Massachusetts 02140 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENT TO PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;23, 2024 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
Stockholders of Vor Biopharma Inc.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement supplement, dated May&nbsp;2, 2024 (this &#147;Supplement&#148;), supplements the definitive
proxy statement on Schedule 14A of Vor Biopharma Inc. (the &#147;Company&#148;), dated April&nbsp;29, 2024 (the &#147;Proxy Statement&#148;), for the Company&#146;s Annual Meeting of Stockholders to be held on May&nbsp;23, 2024 (the &#147;Annual
Meeting&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN
THE PROXY STATEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of Fouad Namouni, M.D., as a Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;30, 2024, the Board of Directors of the Company (the &#147;Board&#148;) (i) increased the authorized size of the Board from six to seven members
and (ii)&nbsp;upon recommendation of the Nominating and Corporate Governance Committee of the Board (the &#147;Nominating Committee&#148;), appointed Fouad Namouni, M.D., as a Class&nbsp;II director of the Company to fill the vacancy created by the
aforementioned increase in the size of the Board, with a term of office expiring at the Company&#146;s 2026 Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on a
review of all relevant identified transactions or relationships between Dr.&nbsp;Namouni, or any of his family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that Dr.&nbsp;Namouni
is an independent director pursuant to the applicable Nasdaq Stock Market listing standards and those rules&nbsp;and regulations issued pursuant to the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Namouni, 55, has served as President, Research and Development of Blueprint Medicines Corporation (&#147;Blueprint&#148;), a global biopharmaceutical
company, since September 2020. Prior to Blueprint, Dr.&nbsp;Namouni served in various leadership roles at Bristol Myers Squibb Company (&#147;BMS&#148;) since 1999, most recently as Senior Vice President and Head of Oncology Development from August
2016 to April 2020 with the responsibility for driving product development plans across a portfolio of drug candidates. Previously, Dr.&nbsp;Namouni served as Head of Global Medical Affairs at BMS from September 2015 to September 2017 and Head of
Development at BMS for OPDIVO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (nivolumab) and YERVOY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (ipilimumab) from January 2011 to September 2015. Dr.&nbsp;Namouni previously
served as a member of the board of directors of Aprea Therapeutics Inc. from June 2020 to May 2022. Dr.&nbsp;Namouni has more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a
pediatric oncologist. He holds an M.D. from the University of Annaba Medical School in Algeria and a Pediatrics degree from Universit&eacute; Rene Descartes in Paris, France. Additionally, Dr.&nbsp;Namouni received a Pediatric Oncology and
Hematology degree and an M.S. in clinical and experimental pharmacology from Universit&eacute; Paris-Sud in France. The Company believes that Dr.&nbsp;Namouni is qualified to serve on the Board due to his experience in oncology and cancer
immunotherapy drug development and his service in leadership roles and as a director of other biotechnology companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his service as
a director, Dr. Namouni will receive the Company&#146;s standard <FONT STYLE="white-space:nowrap">non-employee</FONT> director cash and equity compensation under its <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Compensation
Policy, which is filed as Exhibit 10.1 to the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended March&nbsp;31, 2023, as filed with the Securities and Exchange Commission (the
&#147;SEC&#148;) on May&nbsp;11, 2023. Pursuant to the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Compensation Policy, Dr. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Namouni will receive a cash retainer fee of $40,000 for service as a director and $4,000 for service as a member of the Nominating Committee, payable in equal quarterly installments in arrears on
the last day of each fiscal quarter, in each case <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on days served in the applicable fiscal quarter. In addition, Dr.&nbsp;Namouni received a stock option to purchase 60,000 shares of the
Company&#146;s common stock on the date of his appointment to the Board and will be eligible to receive a stock option to purchase 30,000 shares of the Company&#146;s common stock on the date of each annual stockholder meeting of the Company,
beginning with the 2024 stockholder meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding between Dr.&nbsp;Namouni and any other person pursuant to which
Dr.&nbsp;Namouni was appointed as a member of the Board, and Dr.&nbsp;Namouni has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as set forth above in this Supplement, Dr.&nbsp;Namouni does not beneficially own any shares of the Company&#146;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are not being asked to vote on
or ratify the appointment of Dr.&nbsp;Namouni at the Annual Meeting. Dr.&nbsp;Namouni, as a Class&nbsp;II director, is not a nominee for election at the Annual Meeting. <B>Accordingly, there is no change to Proposal No.</B><B></B><B>&nbsp;1 &#150;
Election of Two Class</B><B></B><B>&nbsp;III Directors, included in the Proxy Statement.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that any proxy card that you requested or that
we elected to deliver to you has not changed and may still be used to vote your shares in connection with the Annual Meeting. <B>If you have already submitted your vote, you do not need to take any further action.</B> Information on how to vote your
shares and how to change your vote or revoke your proxy is contained in the Proxy Statement. The Company urges stockholders to vote their shares prior to the Annual Meeting by using one of the methods described in the Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g819945g0430225727325.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Ang </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>President and
Chief Executive Officer </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;2, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g819945g0430225727078.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g819945g0430225727078.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 .8# 2(  A$! Q$!_\0
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M=F,?17FGQ \4:UH>NP6VGWGDQ/;+(5\I&^;<PS\P/H*Y7_A87BG_ *"A_P#
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MYLGVR/$T1SZ,.OX'!_"O0G%58:$[,W/B%KO]K^(6MXGS;668DQT+?Q-^?'_
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@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g819945g0430225727325.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g819945g0430225727325.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< 'T# 2(  A$! Q$!_\0
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M*='GCT[1XLB;6+@<-CJ(@>OUK*TRW>Y63_A']UE9R'%UK]]S//Z^7N_'GI0
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M7U.<'(20;84]EC''_?6:W(+>&U@2"WB2**,;41% "CT %2T -1$C141555&
M , "G444 %<YXK\*0^+;"&TGO[NUCC?>1;O@/[,.XKHZ* .(MOAW86-ML.LZ
MFD0ZB*5(5_':HK&NK;P;YQL]/L;SQ#J/]R*YED"]OG?=M4?6M'Q3HFO:CX@,
MLEB-6T41J(K%;W[. W\1D&!OR>G.!Z4LWB34_"^E-/-X/BL-/@&6$5Y H ]E
MR,GVZF@"SX-\(3:)?76J7(CM9;F,1K86TC-%"N<Y)8_,_;/'ZUVM5;&Z%]I]
MM=K')&)XEE"2+AE##.".Q&>:M4 %%)10 M%)10!B^++&ZU+PIJ=E9#=<2P,J
MINQO]5SVW#*Y]ZBTWQ7H-VBP1WL-I,@"-9W!$,L1'\)1L$8Z>G'%;]4[[2M/
MU-0E_96]THX FC#8_.@"47MJ1D7,)'KO%-.HV2];N ?605D'P-X3)R?#>E?^
M B?X4?\ "#^%/^A;TK_P%3_"@#4.K:</O7]J/K*O^--.MZ4.NIV8^LZ_XUG#
MP5X6'3P[I?\ X"I_A2_\(9X8_P"A>TS_ ,!D_P * +I\0:,O75K$?6X7_&F'
MQ+H0ZZUIX_[>4_QJO_PA_AH=- TW_P !E_PI?^$3\.?] +3O_ 9?\* ,3Q!X
M^LK:YM],T6_TR6^N%+FXN+E1!;H."SD'D\\*.3ST%9-K>^#XM3AN=5\0MXDU
M96!B*(9XXVZ?)%$"JGW.3[UV?_"+>'QTT33_ /P'7_"M2"W@M(A%;PI%&.BH
*H H FHI** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
